You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Adcendo funding boosts antibody-drug conjugates development

Adcendo – a company that concentrates on the development of breakthrough antibody-drug conjugates (ADCs) for treating cancers with high unmet medical needs – has revealed that it has successfully completed vital funding.